Although glucagon-like peptide-1 (GLP-1) receptor agonists reduce the risk of myocardial infarction (MI), stroke, and CV death in patients with T2DM, they are not recommended for the prevention of HF events [6]. Here, GCG is linked to type 2 diabetes mellitus.